Virpax Pharmaceuticals Announces Reverse Stock Split
Written by Emily J. Thompson, Senior Investment Analyst
0mins
Source: Newsfilter
Reverse Stock Split Announcement: Virpax Pharmaceuticals will implement a 1-for-25 reverse stock split effective March 20, 2025, to comply with Nasdaq's minimum bid price requirement and enhance the attractiveness of its shares to investors.
Company Overview: Virpax focuses on developing non-addictive pain management products and has several drug candidates in the pipeline, including Probudur™ for post-operative pain and Envelta™ for acute and chronic pain management.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
